# RPRX catalysts: Royalty Pharma plc PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rprx/catalysts

> Royalty Pharma plc (RPRX) has no upcoming catalysts in this calendar. The latest recorded is the Royalty Pharma plc earnings report, November 4, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Royalty Pharma plc |
| Ticker | RPRX (Nasdaq) |
| SEC CIK | 1802768 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/rprx |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan 2023 | [PT027 FDA approval](https://sec-api.dev/pdufa/pt027) | RPRX |  | completed, approved | "In May 2018, we entered into an agreement with Avillion II, which was subsequently amended, to fund a total of $155 million over multiple years for a portion of the costs of Phase 2 and 3 clinical trials to advance Airsupra, formerly known as PT027, which was approved by the FDA in January 2023." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000003/rprx-20251231.htm)) |
| September 26, 2024 | [Royalty Pharma plc PDUFA date](https://sec-api.dev/companies/rprx/catalysts) | RPRX | schizophrenia in adults | scheduled | "The NDA for KarXT for the treatment of schizophrenia in adults was accepted for review by FDA, with a PDUFA date of September 26, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1802768/000180276825000010/rprx-20241231.htm)) |
| February 11, 2025 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "NEW YORK, NY, February 11, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000119312525023988/d929959dex991.htm)) |
| April 3, 2025 | [Royalty Pharma plc PDUFA date](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | scheduled | "Cabometyx PDUFA date is April 3, 2025. 7." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000119312525005038/d919433dex991.htm)) |
| May 8, 2025 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "ROYALTY PHARMA REPORTS FIRST QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000119312525115482/d938501dex991.htm)) |
| July 27, 2025 | [Royalty Pharma plc PDUFA date](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | scheduled | "The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of July 27, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000119312525023988/d929959dex991.htm)) |
| August 6, 2025 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "ROYALTY PHARMA REPORTS SECOND QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000119312525173988/d90343dex991.htm)) |
| November 5, 2025 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "ROYALTY PHARMA REPORTS THIRD QUARTER 2025 RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276825000113/rprx-20250930rpplcpressxre.htm)) |
| 2026 | [Cliramitug topline data readout](https://sec-api.dev/pdufa/cliramitug) | RPRX |  | scheduled | "Lastly, our strong financial performance has allowed us to raise our top-line guidance for the second time this year, driven by the strength of our diversified portfolio." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260630rpplcpressxre.htm)) |
| February 11, 2026 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "NEW YORK, NY, February 11, 2026 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2025 and introduced full year 2026 guidance for Portfolio Receipts." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000002/rprx-20251231rpplcpressxre.htm)) |
| May 6, 2026 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "Royalty Pharma reports first quarter 2026 results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm)) |
| August 5, 2026 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "Royalty Pharma reports second quarter 2026 results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000014/rprx-20260630rpplcpressxre.htm)) |
| August 25, 2026 | [Royalty Pharma plc PDUFA date](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | scheduled | "The FDA has set a Prescription Drug User Fee Act target action date of August 25, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000008/rprx-20260331rpplcpressxre.htm)) |
| November 4, 2026 | [Royalty Pharma plc earnings report](https://sec-api.dev/companies/rprx/catalysts) | RPRX |  | completed | "Royalty Pharma reports third quarter 2026 results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1802768/000180276826000026/rprx-20260930rpplcpressxre.htm)) |

## Drugs

- [Cliramitug](https://sec-api.dev/pdufa/cliramitug): 
- [PT027](https://sec-api.dev/pdufa/pt027): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rprx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RPRX catalysts: Royalty Pharma plc PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rprx/catalysts

```bibtex
@misc{secapidev_companies_rprx_catalysts_20261116,
  title        = {RPRX catalysts: Royalty Pharma plc PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rprx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rprx_catalysts_20261116","title":"RPRX catalysts: Royalty Pharma plc PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rprx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
